文献速递主动脉疾病

感染性自体胸主动脉瘤腔内修复术结局:日本多中心研究

Outcomes of Endovascular Repair for Infected Native Thoracic Aortic Aneurysms: A Japanese Multicentre Study.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2025-11-05

中位随访2.5年期间31%发生感染相关并发症,30天和5年总生存率分别为92%和63%。MRSA感染和术前发热(≥38°C)为不良结局的独立预测因素。

要点

  • TEVAR可为高危感染性胸主动脉瘤患者实现急性稳定,但晚期治疗失败仍是显著挑战。
  • MRSA感染和术前发热(≥38°C)是TEVAR后不良结局的独立预测因素。
  • 出现并发症者抗菌治疗中位时长显著短于未出现者(32.5天 vs 162天;p=.027)。

核心结论

  • TEVAR能为高危感染性自体胸主动脉瘤患者提供成功的急性稳定,但晚期治疗失败仍是显著挑战。
  • MRSA感染和术前发热(≥38°C)是TEVAR后不良结局的两个关键独立预测因素。
  • 抗菌治疗时长不足可能促成治疗失败,TEVAR的成功 critically 依赖于以延长感染控制为优先的多学科策略。

研究设计与样本

  • 回顾性多中心研究,使用日本支架移植物管理委员会(JACSM)登记数据(2016-2018年)。
  • 纳入标准严格,要求具备感染的临床、实验室和影像学证据。
  • 主要结局为感染相关并发症,次要结局为总生存率和免于感染性动脉瘤相关死亡。

主要发现

  • 中位随访2.5年期间,24例(31%)发生感染相关并发症。
  • 出现并发症者抗菌治疗中位时长显著短于未出现者(32.5天 vs 162天;p=.027)。
  • 30天总生存率为92%,5年总生存率为63%。
  • MRSA感染和术前发热(≥38°C)为不良结局的独立预测因素。

关键数值与推荐

  • 抗菌治疗中位时长:出现并发症者32.5天 vs 未出现者162天(p=.027)。
  • 总生存率:30天92%,5年63%。

临床怎么用

  • TEVAR可作为高危感染性自体胸主动脉瘤患者的急性稳定手段,但需警惕晚期感染相关失败。
  • 对MRSA感染或术前发热(≥38°C)患者应强化感染控制策略并延长抗菌治疗。
  • TEVAR成功依赖多学科协作,感染控制应作为长期管理核心。

局限性

  • 回顾性研究设计,存在选择偏倚可能。
  • 抗菌治疗时长与并发症的关联为观察性结果,不能确立因果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Infected native thoracic aortic aneurysms (INTAAs) are life threatening emergencies. Although open surgery remains the definitive treatment, thoracic endovascular aortic repair (TEVAR) is a less invasive option for high risk patients. However, its long term efficacy in controlling infection is unclear. This study evaluated the outcomes of TEVAR for INTAAs in a Japanese multicentre cohort. METHODS: This was a retrospective multicentre study using data collected from the Japanese Committee for Stentgraft Management (JACSM) registry (2016 - 2018). Patients were included on the basis of strict criteria requiring clinical, laboratory, and imaging evidence of infection. The primary outcome was infection related complications. Secondary outcomes were overall survival and freedom from infected aneurysm related death. RESULTS: Seventy-eight patients (mean age, 75.6 years; 72% men) met the inclusion criteria. Over a median 2.5 year follow up, infection related complications occurred in 24 patients (31%). The median duration of antimicrobial therapy was statistically significantly shorter in patients who developed complications than in those who did not (32.5 days vs. 162 days; p = .027). The overall survival rate was 92% at 30 days and 63% at five years. Infection with methicillin resistant Staphylococcus aureus (MRSA) and pre-operative fever (≥ 38°C) were independent predictors of poor outcomes. CONCLUSION: TEVAR provides successful acute stabilisation for high risk patients with INTAA, but late treatment failure remains a notable challenge. This study identified two key independent predictors of poor outcomes: infection with MRSA and pre-operative fever (≥ 38°C). Furthermore, the findings suggest that an insufficient duration of antimicrobial therapy contributes to treatment failure. Therefore, the success of TEVAR is critically dependent on a robust, multidisciplinary strategy that prioritises prolonged infection control, especially in patients presenting with these high risk features.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Banno H, Kumamaru H, Akita N, et al. Outcomes of Endovascular Repair for Infected Native Thoracic Aortic Aneurysms: A Japanese Multicentre Study. Eur J Vasc Endovasc Surg. 2025. PMID: 41202866. doi:10.1016/j.ejvs.2025.09.064

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。